Sarepta Therapeutics (NASDAQ:SRPT) shares plummeted on Friday following reports of a third patient death linked to its gene therapy pipeline this year, further clouding investor confidence despite the company’s recent efforts to provide clarity on its restructuring and FDA label plans.
The latest fatality, a 51-year-old man participating in a clinical trial for SRP-9004, the company’s gene therapy for the treatment of limb-girdle muscular dystrophy (LGMD) type 2D/R3, suffered acute liver failure, a cause of death also reported in two earlier fatalities associated with Sarepta’s approved Duchenne muscular dystrophy treatment, Elevidys.
